# Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

> **NCT04609176** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 64 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab plus Apatinib and SOX
- **DRUG:** Camrelizumab plus Apatinib

## Key facts

- **NCT ID:** NCT04609176
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2023-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609176, "Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04609176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*